Introduction
The initial concept of gene transfer for the treatment of genetic diseases has evolved to utilizing this technology to develop molecular therapeutics to treat several acquired and environmental conditions. The FDA definition of gene therapy is 'y a medical intervention based on modification of genetic material of living cells. Cells may be modified ex vivo for subsequent administration or may be altered in vivo by gene therapy products given directly to the subject.' 1 The majority of work in the field of gene therapy has focused on the development of efficient mechanisms of gene delivery. 2 While naked DNA and liposomes can transduce cells, most advances in gene therapy have been made with viral vectors because of their high efficiency in transducing cells in vivo. Inherent to using viruses as vector systems for gene delivery is the subsequent immune response. The central role of cellular and humoral immune responses against vector and transgene products has been appreciated since the earliest attempts of in vivo gene transfer. 3, 4 Several components of the immune system participate in the generation of a coordinated cascade of events, which culminate in the activation of effector cells, namely cytotoxic T cells and antibody secreting plasma cells ( Figure 1 ). While cytotoxic T cells eliminate transduced cells, neutralizing antibodies prevent readministration of the vector. Immune responses directed against the antigens of the viral vector backbone have been shown to eliminate transduced cells in vivo. 5 Rejection of cells expressing the transgene or the generation of transgenespecific antibody responses also contributes to the transient nature of gene expression. 6 This review focuses on dissecting the immune responses, innate immunity, vector-and transgene-specific immune responses, involved in adenoviral and adeno-associated virus (AAV) vector-mediated gene therapy.
Activation of antigen-presenting cells (APC) is central to the induction of an immune response
The first barrier for infections is the innate immunity, which is comprised of neutrophils, tissue macrophages, NK cells, a host of soluble factors including complement, antimicrobial agents and inflammatory cytokines. Professional APC, such as macrophages and dendritic cells (DCs), reside in the various tissues throughout the body in an immature state. In this state, DC express very low levels of major histocompatibility complex (MHC) class I and class II molecules, and other accessory and costimulatory molecules such as CD40, CD54, CD80, CD86. Immature DCs have a high level of phagocytic activity, enabling efficient capture of antigens. 7 The nature of the initial interaction between DC and pathogenic antigens is critical for the subsequent cascade of events, which culminate in an effector T-and B-cell response. This initial interaction, although nonspecific, has been shown to be heterogenous, depending on the engagement of a variety of innate receptor-ligand-induced signals. 8 In this respect, APC recognize 'pathogen-associated molecular patterns' (PAMP), which distinguish self-from nonself antigens, and initiate the induction of an adaptive immune response. This initial interaction of pathogen with APC delivers signals to the APC, which have been referred to as 'danger' signals. 9 Examples of these molecules and their receptors on cells include lipopolysaccharide -CD14/Toll-like receptor (TLR) 2 and 4; unmethylated CpG DNA -TLR9; heat-shock proteins -CD19 and others. 10 These interactions initiate signal transduction pathways, leading to the activation of transcription factors, such as NF-kB that induce secretion of 'inflammatory' cytokines like IL-6, TNFa, MIP1a, MIP1b and IL-1b. These cytokines activate APC functions such as phagocytosis, expression of MHC molecules and other costimulatory molecules on DC. This process of activation is termed 'maturation'. Mature DC, loaded with antigenic peptides, migrate to draining lymph nodes, directed by the induction of a battery of chemokines and their respective receptors. 11 In the lymphoid organs, these MHC-antigenic peptide complexes interact with a high degree of specificity with the T-cell receptor (TCR) on naïve T cells, delivering signal 1.
Complete activation of T cells, however, requires two signals: one transduced by recognition of antigen in the context of MHC class II molecules (see above), and the second by costimulatory molecules, for example, CD28. Several studies have suggested that interaction of CD40L on T cells with CD40 on APC leads to the upregulation of CD80/CD86 molecules on APC which in turn bind to CD28 on T cells, delivering signal 2. 12 Nonself antigens that are delivered in such a way that T cells only receive signal 1 will either be ignored or induce tolerance by deletion or anergy. Delineation of critical events leading to complete T-cell effector function has allowed development of novel strategies in the regulation of immune responses, which may ultimately lead to long-term transgene expression following gene therapy. Furthermore, since the initial 'danger signal' to APC (signal 0) by the pathogen induces activation of the costimulatory pathway, absence of this signal could result in lack of Tcell responsiveness, despite the presence of specific antigen.
We have discussed the use of adenovirus and adenoassociated viral vectors to delineate the necessity of the 'danger' signals to induce immune responses. Vector systems that lack the ability to induce these signals, or alternatively, blocking these initial inflammatory responses, will be useful in generating novel mechanisms to inhibit immune responses in gene therapeutic applications.
Adenovirus vectors
Adenoviruses are nonenveloped DNA viruses with B36-40 kb genomes. There are more than 50 human adenovirus serotypes; however, most of the recombinant adenoviral vectors used in gene therapy applications are based on serotypes 2 and 5. 13 The viral capsid consists of 252 capsomeres, 240 hexon and 12 penton molecules. Each penton base has a large fiber protein. The viral capsids interact with the coxsackievirus adenovirus receptor (CAR) and coreceptors like integrins a5b1, avb3, avb5, aMb2 to infect permissive cells. Subsequent to entering the cells, the virus escapes endosomal lysis and enters the nucleus by traversing microtubules, binds to the nuclear envelope and inserts its genome through nuclear pore complexes. The early gene products of the E1A and E1B genes are the predominant transcription factors that transactivate the other gene products E2, E3 and E4, all of which are necessary for virus replication. During the late stage of transcription, structural genes are transcribed from the L1-L5 genes, which encode among other gene products, the hexon, penton and fiber proteins. Although E3 gene products do not play a role in viral replication, these proteins are involved in modulating a variety of host genes, such as protection from apoptosis, blocking antigen presentation and cell cycle arrest. The functions of the various early and late gene products have been reviewed elegantly elsewhere. 14 A wide range of cell types, for example, respiratory epithelial cells, myoblasts, glial cells, macrophages and hepatocytes have been shown to be infectible with adenoviral vectors, albeit to different degrees. Adenoviruses have been associated with a number of infectious diseases in normal subjects, for example, upper respiratory infections and conjunctivitis, and in immunecompromised hosts have caused liver, kidney and urinary tract infections. The prevalence of adenovirus in the human population has been assessed by serological evaluation of the antibodies against the various adenoviral strains. It was demonstrated that almost all subjects tested (from North America) have immunoglobulins to adenovirus type 5 of which 55% were neutralizing. 15 In addition to adenovirus type 5, serotypes 2, 7 and 17 of human adenovirus 16, 17 and animal adenoviruses 18, 19 have been used as vectors for studies of gene transfer. It is hypothesized that neutralizing antibodies directed against the knob and fiber domains of the viral capsid play a significant role in blocking infection. Utilizing alternative serotypes, not prevalent in the human population, will therefore help in overcoming the barrier of neutralizing antibodies in inhibiting in vivo gene transfer.
A panel of different recombinant adenoviral vectors has been generated over the last couple of years. E1A Immunity to viral vectors K Jooss and N Chirmule and E1B were deleted in the so-called first-generation adenoviral vectors in order to generate replicationdeficient recombinant adenoviral vectors for gene therapy applications. Transient gene expression, because of the activation of cellular and humoral immune responses, 5 prompted investigators to further cripple adenoviral vectors, which generated the second-generation adenoviral vectors containing deletions or modification of E2A, E3 and E4 genes. Furthermore, adenoviral vectors with deletion of all viral gene products, called 'gutless vectors', have been generated. [20] [21] [22] Finally, in order to exploit the cytotoxic functions of wild-type adenoviruses, replication-competent adenovirus vectors have also been utilized in applications involving treatment of tumors. Investigators have taken different approaches for generating these replication-competent, tumor-specific adenoviral vectors. One approach taken to make these vectors tumor specific was to limit the expression of essential viral genes such as E1 to tumor tissues through the use of tumor-specific promoters. 23 Another approach involved the deletion of viral gene functions critical for efficient viral replication in normal cells but dispensable in tumor cells. In this respect, McCormick and co-workers 24 have used an E1b-55 kDa-deleted adenovirus that replicates selectively in p53-deficient tumor cells. The utility of adenoviral vectors in gene therapy has been reviewed extensively. 25, 26 Thus, recombinant adenoviruses offer many advantages for transducing genes in vivo, including efficiency of infecting nondividing cells, robust and rapid transgene expression and ability to generate high-titers of vector. 27 
Adeno-associated virus (AAV) vectors
The wild-type AAV is a single-stranded DNA virus of the Parvovirinae subfamily consisting of a 4.7 kb genome. 28 Four proteins essential for viral replication (Rep) and three structural proteins (capsid or Cap) are encoded from one open reading frame (ORF) each. The open reading frames are flanked on either side by 145 nucleotide (nt) inverted terminal repeat (ITR) sequences that are critical elements for virus replication, packaging and host cell integration. Wild-type AAV virus persists in a latent form within infected cells either in an extrachromosomal state or integrated into the host genome, which occurs in a site-directed manner in the q arm of chromosome 19. 29, 30 In nature, adenovirus and herpes simplex virus (HSV) serve as helper viruses resulting in replication of the AAV virus. Until recently, six AAV serotypes had been isolated and intensively studied which differed in the amino-acid sequence of the viral capsid and crossneutralized each other to various degrees. 31 Recently, Gao et al 32 reported the isolation of two new AAV serotypes from rhesus monkeys, namely AAV-7 and 8. Sequence comparisons among AAV-7 or -8 and AAV 1-6 revealed the greatest divergence in capsid proteins and AAV-7 or -8 are not neutralized by heterologous antisera raised to the other serotypes. AAV-7 or -8 are therefore alternative AAV serotypes for treating patients with pre-existing neutralizing antibodies to AAV 1-6. The predominant AAV serotype used to date for gene therapy applications is AAV-2 on which this review will focus unless otherwise specified.
Importantly, none of the wild-type AAV serotypes 1-6 have ever been described as causing any disease in humans.
Recombinant AAV vectors (rAAV), in which the Rep and Cap sequences have been replaced by a heterologous promoter driving the gene of interest, do not contain any viral ORFs, leaving the transgene product as the only source of nonself antigen besides the input capsid proteins. rAAV vectors transduce a variety of cells in vitro and result in efficient gene transfer to postmitotic tissues in vivo, such as the brain, muscle and liver. [33] [34] [35] [36] The onset of transgene expression following rAAV-2-mediated gene transfer to liver or muscle is considerably longer than with adenoviral vectors, with the plateau reached around 4 weeks postvector administration. 37, 38 The delay in the onset of transgene expression is likely because of the requirement of input single-stranded DNA to be converted to a doublestranded form that can serve as a template for DNA transcription. 39, 40 Long-term transgene expression from rAAV vectors is one of the greatest advantages over recombinant adenoviral vectors, and in most studies no cytotoxic T-cell responses to the AAV capsid or transgene product are observed. One drawback of the AAV vector platform is the limited packaging capacity for transgenes.
The ability to transduce and activate APC influences inflammatory responses by viral vectors
The importance of investigating the early innate responses to adenovirus vectors has been underscored by the death of a patient in the clinical trial for gene therapy of ornithine transcarbamylase (OTC) deficiency. 41 The patient had a genetic deficiency of the OTC gene, which encodes for a critical enzyme in the urea cycle. In the dose-escalation trial, this patient received B6 Â 10 13 particles of E1-E4 deleted adenovirus vector expressing OTC. Following intrahepatic administration of the vector, the patient suffered from various acute inflammatory responses and died 2 days later. Analysis of serum cytokines from this patient showed an increased level of IL-6. 42 Another patient in the study, who received the same dose of the vector, also showed high levels of IL-6 and IL-10 cytokines, exhibited some liver toxicity and fever, but recovered completely. The other 16 patients in the dose-escalation study elicited IL-6 and IL-10, without any significant dose-dependent adverse effects. Subsequently, reviews of clinical trials summarizing the use of adenoviral vectors in a variety of morbid, co-morbid and normal volunteers have shown that these vectors were well tolerated at the doses used (B1 Â 10
) by various routes of administration. [43] [44] [45] In clinical trials using replication-competent adenoviral vectors at doses up to 2 Â 10 12 , induction of both IL-1 and IL-6 were observed; however, the vector was well tolerated by patients. 46 Several factors may account for these differences in safety. Patients with OTC deficiency have relatively high levels of fibrotic liver tissue, and a heightened sensitivity to bacterial and viral infections compared to the general population, which can result in hyperammonia and death. 47 A second contributing factor may have been the viral dose tested in the OTC trial, which was approximately 10-fold higher than in any other clinical trial using adenovirus vectors.
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The above observations have underscored the importance of examining inflammatory cytokines as a measure of acute toxicity of viral vectors in gene therapy clinical trials.
Administration of adenovirus vectors in rodents and rhesus monkeys has been shown to induce inflammatory cytokines, IL-6, TNFa, RANTES, interferon-inducible protein (IP-10), IL-8, MIP1a and MIP-2 in the serum. [48] [49] [50] Macrophages and DCs have been implicated as the source of these cytokines. Within 2 h of intravenous administration of the vector, adenovirus particles are observed in the spleen in the macrophage/DC-rich marginal zone region, suggesting that these cells are the primary source of the acute inflammatory response. In this respect, depletion of the Kupffer cells in the liver results in increased cytokine secretion, coinciding with increased levels of vector in the spleen. These observations suggest that the Kupffer cells sequester adenovirus vectors in the liver. When either the number of Kupffer cells becomes limiting (because of the diseased conditions of the liver), or the dose of the vector is more than can be sequestered by them in the liver, the vector disseminates systemically. It has also been demonstrated that adenoviral vectors can directly transduce macrophages and DCs in vivo, resulting in induction of inflammatory cytokines, such as IL-6, IL-12, TNFa and others. Thus macrophage-like cells in nonlymphoid tissues, especially Kupffer cells of the liver, are capable of sequestering adenovirus vector, preventing or limiting dissemination to the lymphoid organs -namely, draining lymph nodes and spleen. This function could have a role in preventing systemic inflammatory responses, and in reducing the immune response to the vector and transgene product. The impact of pre-existing adenovirus-specific immune responses on the induction of an innate immune response has recently been studied in animals. It was found that animals that were previously immunized with adenovirus vectors, showed a higher acute cytokine profile in serum following vector administration than naïve animals. 51 The authors hypothesized that the presence of vector-specific antibodies allow vector uptake through alternate pathways, such as Fc receptor-mediated internalization of antibody-coated vector by cells of the immune system. Overall, the induction of inflammatory cytokines and subsequent cytotoxic T lymphocytes (CTL) responses is dependent, both on the dose of adenovirus and the extent of the systemic circulation of the vector to the lymphoid organs.
The majority of studies on adenovirus-related inflammatory responses have utilized first-generation E1-deleted adenoviral vectors. The contribution of the inflammatory responses by viral proteins expressed by these first-generation vectors has been examined in E1/ E3-and E1/E4-deleted vectors. These modified vectors have been shown to induce lower levels of inflammatory cytokines when injected into animals. Finally, adenoviral vectors deleted of all viral genes (gutted adenovirus vectors) have been demonstrated to induce markedly reduced immune responses. The applications of gutted adenoviral vector for gene therapy need to be carefully examined, with respect to the potential to induce CTL responses to the input viral capsid proteins. Verma and co-workers 52 have demonstrated that inactivated adenoviral vectors can induce CTL resulting in the elimination of transgene-expressing cells. The mechanisms of this pathway have been suggested to involve crosspriming of DCs with viral antigens (see below). Further studies in large animal models, with various routes of administration, will be required for establishing the use of gutted adenovirus vector to induce long-term gene expression for gene therapy.
Another approach for circumventing adenovirus-induced inflammatory responses has been the use of polyethylene glycol (PEG). 53 Coupling of PEG to the viral capsids modifies the ability of the vector to infect APC, thereby reducing inflammatory responses. Animals administered the PEGylated vectors induced reduced levels of both cell-mediated and humoral immune responses, resulting in prolonged transgene expression. 53, 54 The lack of induction of adaptive immune responses was attributed to the inability of PEGylated adenovirus vectors to efficiently transduce APC in vivo. 55 Strategies to decrease vector-induced inflammation could improve safety and decrease the immunogenicity of adenovirus vectors for gene therapy. Several groups have demonstrated that this technology of formulating vectors may be useful for generating safe and effective adenoviral vectors for gene therapy.
In contrast, AAV does not induce inflammation in liver or muscle following gene transfer, and no inflammatory cytokines are measured in the serum of treated mice. 36 Inflammatory responses immediately following rAAVmediated gene transfer are generally observed if rAAV vector preparations contain impurities from CsCl gradient purification. These impurities most likely trigger the innate immune response and/or provide danger signals to DCs emphasizing the importance of optimizing purification methods for this vector technology (unpublished data).
Immune responses to the transgene product are determined by inflammatory responses induced by the viral vector
Several reports have suggested that transgenes delivered using rAAV vectors fail to induce an immune response. In this respect, the Escherichia coli-derived b-galactosidase gene product is stable for prolonged periods of time in mouse and rhesus monkey muscle. 36 When expressed in an adenovirus vector on the other hand, strong CTL responses against the b-galactosidase ensues, which eliminate b-galactosidase expressing myocytes. 56 Furthermore, studies of clotting factor IX (FIX) generated from liver following rAAV-mediated gene transfer have shown that this foreign transgene product does not elicit inhibitory antibodies, resulting in stable transgene expression. 35 This observation again stands in stark contrast to the strong cell-mediated and humoral immune response to FIX in the context of adenoviralmediated gene transfer to mouse liver and muscle, and was interpreted as being due to the lack of inflammatory responses induced by the AAV vector backbone. It has been suggested that the presence of a 'foreign' protein in the absence of an inflammatory response (danger signal) results in tolerance. At first glance, there are three possible explanations for the lack of immune responses to the transgene product by AAV vectors: (i) AAV cannot infect DCs thereby no antigen is presented to T cells, (ii) AAV enters DCs but fails to express the transgene in DC Immunity to viral vectors K Jooss and N Chirmule and (iii) AAV transduces DC in the absence of an inflammatory response leading to poor antigen-presentation resulting in the induction of tolerance.
Interaction of AAV with DCs
Early studies evaluating the interaction between rAAV vectors and DCs demonstrated that DCs isolated from mouse spleen and transduced by rAAV vectors in vitro do not elicit transgene-specific immune responses in vivo when adoptively transferred into immunocompetent animals. 56 Adenoviral vectors evaluated in the same experiment, however, were able to activate strong antigen-specific T-cell responses leading to target cell destruction in tissues expressing the specific antigen. Fluorescent in situ hybridization (FISH) analysis performed on DCs transduced with rAAV vectors only showed that AAV genomes were found in a perinuclear distribution, compared to in intranuclear replication centers when cotransduced with an adenoviral vector. These findings led to the conclusion that AAV can enter DCs, but that postentry blocks interfere with efficient transduction and antigen presentation. Based on subsequent studies, it appears that the maturation state of the DCs at the time of rAAV vector encounter determines the efficiency of transduction and potential for antigen presentation. DCs isolated from spleen contain more mature cells compared to bone-marrow-derived DCs. The latter were used in an adoptive transfer study demonstrating the induction of antigen-specific T-cell responses that resulted in markedly diminished AAVLacZ-transduced gene expression in vivo. 57 However, this was only true if sufficient numbers of immature DCs that were directly exposed to high concentrations of rAAV vectors in vitro were adoptively transferred in vivo. It remains to be proven whether rAAV-mediated gene transfer in vivo will recruit sufficient numbers of immature DCs to the site of vector administration in order to initiate potent T-cell activation. It is to be expected, however, that rAAV vectors may be less efficient than adenoviral vectors in the recruitment of APC considering the lack of inflammatory responses following rAAV-mediated gene transfer. In addition, DCs are sparsely distributed throughout naïve tissues. In support of this hypothesis are studies by Cordier et al 58 demonstrating transient LacZ expression in muscle following rAAV-LacZ mediated gene transfer in a-sarcoglycan-deficient mice. In these transgenic mice, the naïve muscle tissue demonstrates significant degeneration and strong infiltration with DCs circumventing the need of the AAV vector for recruiting these cells.
In agreement with the above-described observations in mice are in vitro data demonstrating efficient transduction of human monocyte-derived DCs with rAAV vectors. 59 Whether immature DCs take up rAAV vectors via a receptor-mediated uptake remains to be determined considering the high phagocytic activity of this cell population. In summary, the current working hypothesis is that rAAV is incapable of recruiting immature APC in high enough numbers to the site of vector administration resulting in lack of T-cell activation and long-term gene transfer as described in many studies utilizing this vector platform. The 'foreign' antigen is therefore not expressed in high enough numbers of APCs to present it efficiently to CD4+ T cells, which are critical in generating both CD8+ cytotoxic T-cell responses and T-cell-dependent B-cell responses.
Viral vectors are efficient in crosspriming
Although most of the studies utilizing rAAV vectors have demonstrated stable gene transfer, certain combinations of rAAV-borne transgene products and target tissues do result in stimulation of immunity, implying that there is no general mechanism by which AAV blunts the immune system. 60, 61 Furthermore, some investigators have successfully used this vector platform in vaccine studies, inducing efficient humoral and cellular responses to the transgene product. 62 In order to understand this discrepancy of rAAV vector performance, the mechanism of T-cell activation in the context of rAAVmediated gene transfer was extensively studied and compared to adenoviral vectors. These studies were performed in T-cell receptor transgenic animals in which the number and activation status of antigen-specific CD4+ T cells can be precisely monitored. 63 The investigators could show that cellular immune responses to the highly immunogenic transgene product hemagglutinin (HA) expressed on the cell surface of myocytes following gene transfer were elicited with both vector systems, resulting in the elimination of transduced muscle fibers within 4 weeks. However, the kinetics of HA-specific CD4+ T-cell activation were markedly delayed when AAV vectors were used as compared to adenoviral vectors. Upon administration of recombinant adenovirus expressing HA (Ad-HA), T cells were activated both by direct transduction of DCs and by crosspresentation of the transgene product (implying uptake of antigen by DCs without direct transduction). On the other hand, after recombinant AAV expressing HA (rAAV-HA)-mediated gene transfer T cells were only activated by the latter mechanism. In this study, DCs isolated from the draining lymph nodes of animals previously transduced with rAAV-HA vector were negative for the HA message as demonstrated by RT-PCR analysis, providing supporting data that demonstrate inefficient DC transduction by rAAV vectors in vivo. Furthermore, DCs isolated from the draining lymph nodes of Ad-HA-transduced animals were positive for the HA message in RT-PCR studies, supporting the in vitro data that show efficient transduction of DCs by adenovirus vectors. Importantly, this is the only study to date that evaluated the interaction between rAAV vectors, Ad vectors and DCs following gene transfer in vivo.
Several studies have utilized tissue-specific promoters to address whether transduction of DCs by viral vectors is central to induction of immune responses. Most recently, Prasad et al 64 studied the influence of adenovirus vectors expressing the influenza virus nucleoprotein, NP, driven under the CMV promoter (which is active in all cell types), surfactant promoter (expression limited to bronchio-alveolar tissue) or keratin promoter (limited expression in keratinocytes). Immunizing mice by various routes of administration demonstrated that all of the tested adenoviral vectors induced NP-specific immune responses. NP-specific immune activation for the vectors expressing NP from tissue-specific promoters was shown to be because of crosspresentation by APCs.
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Taken together, based on the data on the mechanism of crosspresentation, it can be expected that the amount of transgene product synthesized by the transduced cells will likely influence the efficiency of T-cell priming. The expression of antigens in peripheral tissues must be relatively high to facilitate priming of naïve CD8+ T cells by crosspresentation. 65 Thus, the strength of promoters used in rAAV vectors will have an impact on T-cell activation, and low activity and regulatable promoters may facilitate escape from immune recognition. However, it has been shown that antigens that are weakly expressed in peripheral tissues do activate naïve CD8+ T cells via crosspresentation if the target tissue is destroyed. 65 This should be kept in mind in cases where the tissue targeted by gene transfer is inflamed as, for instance, in muscular dystrophies, where even intracellular or nuclear transgene products may become crosspresented because of the excessive cell death. 66 Route of administration determines immune responses to transgene product Adenovirus vectors have been administered in a wide variety of animal models, and humans via many different routes of administration. These vectors consistently induce strong cell-mediated and humoral immune responses. Surprisingly, adenovirus vectors also generate immune responses in mice transgenic for the adenoviral gene products although they should be tolerant to these antigens. 67 However, the strength of signals delivered by/with the antigen, which includes danger signals through inflammatory responses, could play a significant role in the induction/break of tolerance. Adenoviruses, by their ability to induce a strong inflammatory response, fail to induce tolerance effectively in adult mice by any delivery route. In utero and intrathymic administration of adenoviral vectors, however, have induced partial unresponsiveness in newborn mice and sheep. 68, 69 As for AAV vectors, Ge et al 70 demonstrated that the route of administration determines the nature of the humoral immune responses elicited to the transgene product. In this particular study, rAAV vector expressing human Factor IX (hFIX) was administered to mouse liver or muscle. All of the animals that received the vector by the intramuscular (i.m.) route generated a humoral immune response against the transgene product despite expressing only low levels of hFIX in the blood. None of the mice that had received the rAAV-FIX by the vascular route, resulting in high serum levels of hFIX, generated anti-FIX inhibitory antibodies. The target tissue, more so than the level of protein expression, appeared to direct the nature of the humoral immune response to the xenoprotein. It has been speculated that the expression of FIX from muscle results in binding of the protein to the extracellular matrix, leading locally to high concentrations of the xenoprotein, which may result in efficient uptake of antigen by APC via crosspresentation. In contrast, hFIX generated from a secretory tissue like the liver may not reach very high local levels of the xenoprotein and therefore escape immune activation via crosspresentation. This hypothesis is supported by the data demonstrating the induction of immune tolerance to human Factor VIII (hFVIII) by sustained expression of hFVIII from rAAV-transduced hepatocytes. 71 In vivo administration of adenovirus and AAV vectors results in the generation of neutralizing antibodies in various animal models and humans. The presence of vector-specific neutralizing antibodies inhibits vector readministration, especially when administered systemically, for example, in liver or lungs. 72 Interestingly, the blocking effects of neutralizing antibodies for vector readministration have less influence in the muscle, eyes or brain, primarily because of the physical barriers of lymphoid fluids in these organs. 73, 74 Studies in rhesus monkeys have demonstrated that AAV and adenovirus vector elicit markedly different immunoglobulin isotypes. While adenovirus induces IgG1, IgG4 and IgA responses, AAV predominantly induces only IgG1 responses, suggesting that adenovirus vector elicits a wider profile of cytokines, which in turn induces isotype switching. 75 These observations are consistent with the fact that AAV does not induce strong inflammatory responses, thereby resulting in a 'weaker' humoral immune response, which is less long-lived.
Humoral immune responses to viral vectors
In naïve animals, which have no pre-existing vector immunity, immune modulatory agents that block CD4+ T helper cells, for example, anti-CD4 or anti-CD40L antibodies, successfully inhibited the inductive phase of the antibody response, when administered at the time of vector administration, allowing vector readministration. 76 Humans, on the other hand, are exposed to wild-type adenovirus and AAV viruses, and the majority of humans have circulating antibodies to AAV and adenovirus type 5; B60% have neutralizing antibodies to adenovirus and B30% to AAV-2. 15 The presence of these neutralizing antibodies could potentially affect the efficacy of viral vector-mediated gene therapy regimens. In order to achieve efficient gene transfer in patients with pre-existing adenoviral antibodies, investigators have developed affinity columns consisting of recombinant capsid proteins to remove specifically anti-adenovirus antibodies from human serum. 77, 78 Patient serum collected 2 weeks after administration of a replicationcompetent adenoviral vector with an anti-Ad5 neutralizing antibody titer of 1:3200 was passed over the column. The results demonstrated that the adenovirus affinity column could efficiently remove both neutralizing and
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Another approach to overcome the obstacle of pre-existing antibodies is the use of alternate serotypes, for example, adenovirus 2 and 7, or AAV-1, AAV-4, AAV-7 or 8. In addition, since many humans will be pre-exposed to 'human' viruses, several investigators have used animal viruses as vector systems for gene delivery. In this respect, canine, porcine and chimp adenoviruses, and AAV isolated from rhesus monkeys are being tested as vectors for various applications to overcome the barriers of pre-existing neutralizing antibodies. 18, 32, 79 Interference with immune activation to achieve long-term gene transfer
The success of long-term gene therapy is dependent on the ability to avoid the induction of immune responses to both the vector and the transgene product. Significant advances have been made in the development of novel strategies to modulate immune responses in various animal models, both for inhibiting cell-mediated immune responses to prolong transgene expression and humoral immune responses to permit readministration of the vector. A majority of the pharmaceutical intervention strategies that have been extensively investigated in clinical trials for transplantation and are being adapted for gene therapy are inhibitors of cell-mediated immune function. Blocking of costimulation has been shown to inhibit T-cell activation in several animal models of gene therapy. In this respect, CTLA4-Ig and anti-CD40 ligand, which block interactions of B7-CD80/CD86 and CD40-CD40L, have been shown to blunt adenovirus vectormediated induction of CTL responses, resulting in prolonged transgene expression in liver, lung and muscle. 80, 81 These immune modulators, although effective in blunting the induction of primary immune responses, do not induce tolerance, and readministration of adenoviral vectors in the absence of the suppressing agents results in antigen-specific T-cell responses. Interestingly, Sarukhan et al 63 could demonstrate that cellular immune responses to a highly immunogenic transgene product are easier to control in the context of rAAVmediated gene transfer than following recombinant adenoviral-mediated gene transfer. The fact that recombinant adenoviral vectors efficiently transduce and activate DCs, contain an immunogenic backbone as well as initiate innate immune responses, makes it a difficult task to achieve long-term transgene expression. In this respect, administration of E1-deleted adenovirus vectors in CD40L knockout animals results in reduced but significant CTL activity, which ultimately results in the elimination of transgene expression. 76 Thus, blocking of the vector-induced inflammatory process (ie, signal 0) in addition to interfering with costimulatory signals may be necessary to block effectively adenovirus-induced immune responses in gene therapy. For rAAV vectors expressing highly immunogenic transgenes, on the other hand, blocking of the T-cell-APC interaction by using antibodies directed against CD40L resulted in long-term gene transfer. 63 Furthermore, for rAAV vectors investigators were successful in inducing transgene-specific Tcell tolerance to the transgene product, which they failed to achieve in the context of adenoviral-mediated gene transfer.
Conclusions
In summary, the data presented in this review clearly underline the importance of understanding the mechanisms by which vector-encoded proteins are recognized by the immune system as well as how the viral backbone interacts with APCs and DCs specifically. In addition, it emphasizes the importance of understanding how and whether viral vectors activate innate immune responses, a research area that was neglected for a long time. Understanding all of these interactions will enable us to interfere specifically with immune activation in designing vector-specific immune modulations in order to achieve the ultimate goal of safe and stable gene transfer in clinical trials.
